Browsing Tag

DT216

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216…

Eli Pacheco Dec 8, 2022 0

DT-216 was Generally Well-Tolerated and Resulted in a More than Doubling of Frataxin mRNA in Patients with Friedreich Ataxia Second GeneTACTM Development Candidate, DT-168, Selected for…

Health

Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of…

Eli Pacheco Mar 30, 2022 0

Topline Data from Phase 1 Trial Expected in the Second Half of 2022 DT-216 Granted FDA Fast Track Designation for Patients with Friedreich Ataxia CARLSBAD, Calif., March 30, 2022 (GLOBE…